Clinical Trials
6 trialsNCT05509699 2025-08-29
Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer
Hutchmed
Phase 2 Completed
NCT05481463 2025-05-28
Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer
Sun Yat-sen University
Phase 2 Completed
NCT05236699 2025-02-14
CCGLC-005
Tongji Hospital
Phase 2 Completed
NCT04169672 2023-03-02
Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors
Hutchmed
Phase 2 Completed
NCT02614495 2020-02-13
Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma
Hutchmed
Phase 2 Completed
NCT02966821 2019-02-27
Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma
Hutchmed
Phase 2 Completed